Drug intelligence / Profile preview

DPS-102

Development stage: Discontinued
Lead developer: DermiPsor
Modality: Small Molecules
Administration: Topical

Overview

DPS-102 is a non-steroidal, small molecule immunomodulator developed by DermiPsor for the topical treatment of scalp psoriasis. Its mechanism of action is described as immunomodulation, though the precise molecular target has not been disclosed. DPS-102 was investigated in a phase 2 clinical trial for scalp psoriasis but development has since been suspended[1][2][3].

Targets

PARP1 (Poly (adp-ribose) polymerase 1)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on DPS-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPS-102.

Explore the full profile